This case underscores the critical importance of retesting for resistant mechanisms, such as EML4‐ALK fusion, in patients with EGFR‐mutant lung adenocarcinoma who experience rapid progression on EGFR‐tyrosine kinase inhibitor (TKI) therapy. Here, ALK is linked to lung adenocarcinoma.